This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
FOSB / Protein FosB · IHC design guide
Design Immunohistochemistry for FOSB
Plan FOSB IHC in paraffin sections using nuclear staining as the expected pattern (HPA tissue IHC). Compare positive tissue controls with your specimens and score staining in the relevant cell populations.
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
FOSB Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining in several tissues (HPA tissue IHC) | |
| Staining pattern | Nuclear staining in trophoblastic and urothelial cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet RP1086) | |
| Positive control | Placenta+4 more · see all | |
| Negative control | Adrenal gland+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image RP1086) | |
| Caveat | Staining has low consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Staining regulation is unreported (UniProt) | |
| Isoform / epitope | 11 isoforms; epitope coverage needs validation (UniProt) |
Section 1
Recommended FOSB IHC & IF Protocols
The catalog antibody’s IHC-P protocol is paired with 4 published FOSB IHC protocols (PMC3503985; PMC5678090; PMC7085481; PMC12196134).
| Sample | Paraffin-embedded human renal cancer tissue; fixative not specified (datasheet RP1086) |
| Fixation | Image fixative and duration unreported (datasheet RP1086); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet RP1086); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet RP1086) |
| Primary antibody | Rabbit anti-FOSB, 0.5-1μg/ml (datasheet RP1086) |
| Primary incubation | Overnight at 4 °C (datasheet RP1086) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet RP1086) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | FOSB-positive staining in trophoblastic cells of placenta (HPA tissue IHC: High). HPA tissue profile: Nuclear expression in several tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 for the catalog antibody (datasheet RP1086); the osteoid osteoma study used Tris-EDTA at pH 9.0 (PMC7085481).
Section 2
What Is the Expected FOSB Staining Pattern?
FOSB is a nuclear transcription factor with no transmembrane segment (UniProt P53539). In paraffin-section IHC, expect nuclear staining in trophoblastic cells of placenta and urothelial cells of urinary bladder, both scored High by HPA (HPA tissue IHC). HPA reports nuclear expression across several tissues, but rates its IHC data Approved with low consistency between antibody staining and RNA expression (HPA tissue IHC).
| Distinct nuclear chromogen in placental trophoblastic cells or bladder urothelial cells (HPA: High in both). | This fits the expected compartment and cell populations (UniProt P53539: nucleus; HPA tissue IHC). Score the relevant cells separately from surrounding tissue; HPA's High designation describes its observed staining, not a required intensity for every specimen (HPA tissue IHC). |
| Predominantly cytoplasmic or extracellular staining, with little nuclear signal. | This conflicts with the established nuclear location (UniProt P53539; HPA: nuclear tissue expression). Consider nonspecific binding or detection artefact, then check morphology and controls (general IHC practice). HPA reports uncertain vesicle localisation in ICC-IF; that does not validate a cytoplasmic IHC pattern (HPA subcellular). |
| Strong staining in cells listed as Not detected, such as adrenal glandular or marrow hematopoietic cells (HPA tissue IHC). | Treat an unexpected cell-type pattern as possible cross-reactivity or endogenous detection activity, not proof of FOSB expression (general IHC practice). HPA's Not detected calls describe the cited samples and antibody assessment; they are not universal biological negatives (HPA tissue IHC). |
| Diffuse chromogen over nuclei, cytoplasm and stroma, obscuring cell boundaries. | The distribution cannot establish the expected nuclear pattern (UniProt P53539; HPA tissue IHC). Excess antibody, incomplete blocking or endogenous detection activity can produce background (general IHC practice). Compare an appropriately processed negative control before scoring nuclei (general IHC practice). |
| No nuclear staining in placental trophoblasts or bladder urothelium (HPA: High in both). | First assess assay failure using tissue integrity and detection controls (general IHC practice). HPA's High observations make these reasonable positive comparators, but HPA reports low staining–RNA consistency; a blank section alone does not establish biological absence (HPA tissue IHC). |
💡Expected FOSB appearanceCall positive when distinct nuclear chromogen marks placental trophoblasts or bladder urothelium, where HPA reports High staining (HPA tissue IHC; UniProt P53539: nucleus); diffuse stromal or predominantly cytoplasmic color is suspect (general IHC practice).
| Cell and tissue context (HPA tissue IHC). | Placental trophoblasts and bladder urothelium are High; several other cell populations are Medium or Low (HPA tissue IHC). Judge signal in the specified cells, since HPA reports low tissue RNA specificity and low staining–RNA consistency (HPA tissue IHC). |
| Antibody validation (HPA antibodies; HPA tissue IHC). | CAB010267 has Approved IHC status; HPA054663 has Supported ICC status with no IHC status listed (HPA antibodies). These labels are application-specific, and Approved IHC does not remove HPA's stated staining–RNA consistency caveat (HPA tissue IHC). |
| Isoforms and epitope coverage (UniProt P53539). | UniProt lists 11 FOSB isoforms (UniProt P53539). The supplied record does not map the catalog antibody's epitope, so which isoforms it recognizes cannot be inferred; interpret a negative stain within that limitation (UniProt P53539; general assay interpretation). |
| Antigen retrieval (general IHC practice). | Use the IHC-validated antibody's documented paraffin-section conditions as a starting point, and compare retrieval conditions only with suitable controls (general IHC practice). The supplied UniProt and HPA records establish no FOSB-specific retrieval response or fixation sensitivity. |
| IF/ICC Q: What compartment should be checked? (HPA subcellular). | A: Nucleoplasm is the supported main location; vesicles are an uncertain additional location (HPA subcellular). This informs localisation checks only: ICC-IF evidence does not supply an IF protocol option for this IHC-P guide (HPA subcellular; HPA antibodies). |
| Situation | Likely cause | Next action |
|---|---|---|
| Positive comparator is blank: no nuclear color in placental trophoblasts or bladder urothelium (HPA: High). | A staining-run problem, weak detection or unsuitable antibody conditions are possibilities (general IHC practice); HPA does not identify the cause for an individual section. | Check tissue morphology, reagent and detection controls, then review the IHC-validated antibody's documented IHC-P conditions (general IHC practice). Repeat with a matched positive section before calling the specimen negative (general IHC practice). |
| Predominantly cytoplasmic signal obscures nuclei (UniProt P53539: nucleus). | Nonspecific signal or excess background is possible (general IHC practice). HPA's uncertain vesicle observation comes from ICC-IF and does not establish this as an IHC-positive pattern (HPA subcellular). | Inspect nuclear counterstain and cell boundaries; compare a negative control and adjust antibody concentration within documented IHC conditions if needed (general IHC practice). Score only interpretable nuclear staining (UniProt P53539; HPA tissue IHC). |
| Color appears broadly in stromal or cell populations outside the expected positive cells (HPA tissue IHC). | Cross-reactivity or endogenous enzyme activity may contribute in chromogenic IHC (general IHC practice). HPA's tissue calls are cell-specific and its staining–RNA consistency is low (HPA tissue IHC). | Compare a no-primary control, verify blocking and inspect the exact stained cell type (general IHC practice). Avoid assigning FOSB positivity from color alone when the compartment conflicts with nuclear localisation (UniProt P53539). |
| Diffuse background prevents reliable nuclear scoring. | Incomplete blocking, excessive antibody or inadequate washing can elevate nonspecific signal (general IHC practice); the supplied sources give no FOSB-specific cause. | Review blocking, washing and antibody concentration against the documented IHC workflow; process positive and negative controls in the same run (general IHC practice). Reassess only after nuclei are distinguishable (general IHC practice). |
| A specimen disagrees with an HPA Not detected example, such as adrenal glandular cells (HPA tissue IHC). | The sample may differ from HPA's observed material, or the signal may be nonspecific (HPA tissue IHC; general IHC practice). A single discrepant stain cannot distinguish these explanations. | Confirm that staining is nuclear, compare controls and report the cell type and intensity explicitly (UniProt P53539; general IHC practice). Treat the HPA category as a reference observation, not an absolute exclusion (HPA tissue IHC). |
| A clear nuclear signal is present, but its meaning is uncertain because RNA evidence differs (HPA tissue IHC). | HPA rates tissue IHC Approved while explicitly reporting low consistency with RNA expression (HPA tissue IHC). Nuclear localisation supports pattern assessment but does not resolve antibody specificity by itself (UniProt P53539; general IHC practice). | Record compartment, stained cell population and controls; describe the finding as IHC staining with the HPA consistency caveat (HPA tissue IHC). Use independent validation before making a strong biological expression claim (general IHC practice). |
Experiment evidence
IHC & IF images showing FOSB staining
RP1086 · IHCIHC analysis of FOSB using anti-FOSB antibody (RP1086). FOSB was detected in paraffin-embedded section of human renal cancer tissue. Heat me
RP1086 · IHCIHC analysis of FOSB using anti-FOSB antibody (RP1086). FOSB was detected in paraffin-embedded section of human renal cancer tissue. Heat me
A01569-1 · IHCIHC analysis of Fos B/FOSB using anti-Fos B/FOSB antibody (A01569-1). Fos B/FOSB was detected in a paraffin-embedded section of human lung c
A01569-1 · IHCIHC analysis of Fos B/FOSB using anti-Fos B/FOSB antibody (A01569-1). Fos B/FOSB was detected in a paraffin-embedded section of human gallbl
A01569-1 · IFIF analysis of Fos B/FOSB using anti-Fos B/FOSB antibody (A01569-1). Fos B/FOSB was detected in an immunocytochemical section of SiHa cells.
M01569 · IHCIHC analysis of Fos B using anti-Fos B antibody (M01569). Fos B was detected in a paraffin-embedded section of mouse brain tissue. Heat medi
M01569 · IHCIHC analysis of Fos B using anti-Fos B antibody (M01569). Fos B was detected in a paraffin-embedded section of rat brain tissue. Heat mediat
M01569 · IFIF analysis of Fos B using anti-Fos B antibody (M01569) and anti-Beta Tubulin antibody (M01857-3). Fos B was detected in immunocytochemical
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000125740-FOSB/tissue/cerebral+cortex#imid_3097344
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000125740-FOSB/tissue/colon#imid_3097278
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000125740-FOSB/tissue/liver#imid_3097279
HPA · GallbladderHuman Protein Atlas IHC, Gallbladder. Source: https://www.proteinatlas.org/ENSG00000125740-FOSB/tissue/gallbladder#imid_3097247
![HPA ICC-IF BJ [Human fibroblast] — FOSB (HPA054663)](https://images.proteinatlas.org/54663/1534_B6_1_blue_red_green.jpg)
HPA · ICC-IF BJ [Human fibroblast]Human Protein Atlas immunofluorescence, BJ [Human fibroblast], antibody HPA054663; green = FOSB, blue = nucleus, red = microtubules.
![HPA ICC-IF BJ [Human fibroblast] — FOSB (HPA054663)](https://images.proteinatlas.org/54663/1534_B6_2_blue_red_green.jpg)
HPA · ICC-IF BJ [Human fibroblast]Human Protein Atlas immunofluorescence, BJ [Human fibroblast], antibody HPA054663; green = FOSB, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for FOSB IHC & IF
🧪Run placenta first and look for FOSB staining in trophoblastic cells (HPA: High). Use adrenal gland glandular cells as the negative tissue (HPA: Not detected); on the placenta slide, use cells without specific nuclear staining to assess background, without assuming every other cell type is negative (UniProt P53539: nucleus).
Positive control tissue: Placenta (Trophoblastic cells, HPA High)
Negative control tissue: Adrenal gland (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show FOSB in BJ [Human fibroblast], SiHa, U2OS, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control; a rabbit IgG control matched to the primary antibody’s clonality; and FOSB knockout material or a validated peptide-block control (caption: rabbit anti-FOSB antibody). For placental sections developed with the caption’s streptavidin–biotin/DAB method, control endogenous peroxidase and biotin before interpreting staining (caption: SABC with DAB).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected RP1086 tissue-IHC caption does not state a fixative (RP1086 caption). The paraffin-section example uses heat-mediated EDTA retrieval at pH 8.0; that documents one workable retrieval condition, not a requirement for every specimen (RP1086 caption). ICC-IF images exist for BJ, SiHa and U2OS cells, but the supplied evidence does not establish that IF or frozen sections are easier than paraffin IHC; placental endogenous biotin can complicate the caption’s streptavidin–biotin detection method (HPA subcellular; RP1086 caption).
HPA tissue IHC evidence for FOSB
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Placenta | Trophoblastic cells | High | Protein (IHC) | HPA → |
| Urinary bladder | Urothelial cells | High | Protein (IHC) | HPA → |
| Adipose tissue | Adipocytes | Medium | Protein (IHC) | HPA → |
| Lymph node | Non-germinal center cells | Medium | Protein (IHC) | HPA → |
| Ovary | Ovarian stroma cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced FOSB IHC Tips
Troubleshoot FOSB staining in paraffin sections by checking retrieval, nuclear localisation, cell identity and controls before interpreting signal intensity.
What retrieval should I start with for weak FOSB staining in paraffin sections?
Start with heat-mediated antigen retrieval in EDTA at pH 8.0 (datasheet RP1086). The catalog antibody produced a FOSB tissue image with that retrieval condition, so use it as the reference when comparing runs (datasheet RP1086). If nuclear staining remains weak, adjust heating and cooling within your laboratory’s established retrieval workflow while keeping section thickness, antibody concentration and detection constant (standard IHC practice). Include a placenta section with trophoblastic cells as a positive reference and inspect nuclear signal before increasing DAB development, since those cells show high FOSB staining in the tissue atlas (HPA: High in placental trophoblastic cells).
How should I investigate a fixation-related loss of FOSB staining?
The selected tissue image identifies a paraffin section but does not report its fixative, so target-specific fixation sensitivity is unknown (datasheet RP1086: fixative not stated). Record the fixative, fixation duration and processing history for every section, then compare matched specimens processed under the laboratory’s established conditions (standard IHC practice). Keep EDTA retrieval at pH 8.0 and the remaining staining steps constant during that comparison (datasheet RP1086; standard IHC practice). Interpret a loss of nuclear staining only alongside tissue morphology and a positive reference section; damaged morphology can make either weak staining or apparent absence difficult to assess (standard IHC practice).
Where should convincing FOSB signal appear in a chromogenic section?
Prioritise staining within intact nuclei: FOSB is annotated as nuclear, and the tissue atlas reports nuclear expression across several tissues (UniProt P53539: subcellular location; HPA: tissue profile). A nucleoplasmic pattern has additional support from cell imaging, whereas the reported vesicular location is uncertain (HPA: subcellular summary). Compare DAB signal with the haematoxylin counterstain at high magnification, checking that positive profiles belong to identifiable cells rather than extracellular material (standard IHC practice). If staining is predominantly cytoplasmic, inspect section quality, background and antibody specificity before assigning it to FOSB; the protein has no annotated transmembrane segment (UniProt P53539: topology).
Can this stain distinguish full-length FOSB from its other isoforms?
Do not assign a stained nucleus to one FOSB isoform without an epitope map and isoform-specific validation: the record lists 11 isoforms (UniProt P53539: isoforms). The canonical protein contains a bZIP domain at residues 155–218 and a reported phosphoserine at residue 27, but the supplied caption does not locate the antibody epitope (UniProt P53539: domains and modified residues; datasheet RP1086). An epitope shared by isoforms could yield a combined signal, while an omitted or masked region could alter detection (standard immunohistochemistry principle). Report results as FOSB immunoreactivity unless the antibody’s epitope and isoform selectivity have been established for the tested sections (standard IHC practice).
How should I assess FOSB in a multiplex IF experiment?
For an IF experiment, assess nuclear FOSB alongside a validated marker of the expected cell type; placental trophoblastic cells provide one tissue context with high FOSB staining (UniProt P53539: subcellular location; HPA: High in placental trophoblastic cells). Choose a fluorophore whose emission is well separated from measured tissue autofluorescence, and include single-stain controls to check spectral overlap (standard IF practice). Because FOSB is nuclear and has no transmembrane segment, permeabilisation must allow antibody access to intracellular nuclear epitopes (UniProt P53539: subcellular location and topology; standard IF practice). Optimise that step for the chosen preparation and evaluate localisation within nuclear boundaries; the supplied paraffin IHC caption does not specify IF conditions (datasheet RP1086).
How can I reduce diffuse DAB staining without losing nuclear FOSB?
First compare stained sections with a no-primary control to distinguish antibody-associated signal from detection-system background (standard IHC practice). The selected image used 10% goat serum blocking, 1 μg/ml catalog antibody overnight at 4°C, a biotinylated secondary and DAB development (datasheet RP1086). Check blocking, washing, secondary compatibility and endogenous peroxidase quenching within your general chromogenic workflow before increasing retrieval or DAB exposure (standard IHC practice). Because the pictured workflow uses biotin-based detection, assess background from that detection route with an appropriate control; accept changes only if discrete nuclear staining remains visible in a positive reference (datasheet RP1086; standard IHC practice).
What is a defensible way to quantify FOSB-positive cells? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and nuclear scoring threshold before examining experimental groups, then apply the same rules to every section (standard IHC practice). Record the percentage of positive nuclei and, if staining intensity is reproducible, an H-score from 0–300; report positive nuclear density per mm² when cell abundance itself matters (standard IHC practice). Normalise each count to all evaluable nuclei in the specified cell population, or density to the measured viable tissue area, rather than to the entire slide (standard IHC practice). Keep retrieval, imaging and DAB development consistent, and disclose that tissue atlas staining has low consistency with RNA expression data (datasheet RP1086; HPA: Approved, low consistency).
How do I separate genuine FOSB positivity from staining artefacts?
Look for discrete nuclear staining in intact, identifiable cells, consistent with FOSB’s nuclear annotation and the tissue atlas nuclear profile (UniProt P53539: subcellular location; HPA: tissue profile). Placental trophoblastic cells and urinary bladder urothelial cells show high staining in the atlas, but cell identity must still be checked in the section being scored (HPA: High in those cell types; standard IHC practice). Treat staining concentrated at section edges, in necrotic regions or outside nuclei as suspect until controls support it (standard IHC practice). A no-primary control and endogenous peroxidase control help identify chromogenic artefacts; a positive reference helps assess whether a negative result reflects the staining run (standard IHC practice).
Boster reagents
Best FOSB / Protein FosB IHC Antibodies
Anti-FOSB antibodies have paraffin-section IHC images from human and mouse tissues and IF/ICC images from SiHa and HeLa cells (catalog image captions).
Real IHC data
Anti-Fos B/FOSB Antibody ®
Cat # RP1086
Real IHC data
Anti-Fos B/FOSB Antibody
Cat # A01569-1
Real IHC data
Anti-Fos B Rabbit Monoclonal Antibody
Cat # M01569
RP1086 has IHC images from human renal cancer and mouse intestine; A01569-1 has IHC images from human lung cancer, gallbladder adenocarcinoma, and placenta (respective IHC captions). M01569 has IHC images from mouse and rat brain, while A01569-1 and M01569 have IF/ICC images from SiHa and HeLa cells, respectively (respective image captions).
Which to pick: For tissue IHC, choose RP1086 for human renal cancer or mouse intestine, or A01569-1 for the pictured human tissues; each SKU’s IHC caption documents paraffin sections and EDTA pH 8 retrieval (respective IHC captions). For IF/ICC, choose A01569-1 for human SiHa cells or monoclonal M01569 for HeLa cells; both list IF/ICC, while RP1086 does not (catalog applications; IF captions; M01569 clone DFO-6). For cross-species IHC, M01569 has mouse and rat brain images, and RP1086 has human and mouse tissue images; both list human, mouse, and rat reactivity, but their IHC captions do not report the fixative (catalog reactivity; respective IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P53539 (FOSB_HUMAN, Protein FosB).
- Human Protein Atlas. FOSB tissue IHC expression (reliability: Approved).
- Human Protein Atlas. FOSB subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to vesicles..
- Human Protein Atlas. FOSB antibody validation summary (2 antibodies).
- Glucocorticoids regulation of FosB/ΔFosB expression induced by chronic opiate exposure in the brain stress system. PloS one 2012 — PMC3503985.
- Brain activation induced by chronic psychosocial stress in mice. Scientific reports 2017 — PMC5678090.
- Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma. Virchows Archiv : an international journal of pathology 2020 — PMC7085481.
- Anxiolytic and Antidepressant Effects of Organic Polysulfide, Dimethyl Trisulfide Are Partly Mediated by the Transient Receptor Potential Ankyrin 1 Ion Channel in Mice. Pharmaceutics 2025 — PMC12196134.
- PubMed PMID:1301997 — UniProt-cited evidence.
- PubMed PMID:8985116 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for FOSB (Protein FosB). Expected localisation Nuclear staining in several tissues (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet RP1086). Validated IHC antibody: RP1086 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Placenta (Trophoblastic cells); negative Adrenal gland. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded human renal cancer tissue; fixative not specified (datasheet RP1086); 2. Fixation: Image fixative and duration unreported (datasheet RP1086); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet RP1086); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet RP1086); 8. Primary antibody: Rabbit anti-FOSB, 0.5-1μg/ml (datasheet RP1086); 9. Primary incubation: Overnight at 4 °C (datasheet RP1086). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image RP1086); Caveat: Staining has low consistency with RNA expression (HPA tissue IHC); Isoform / epitope: 11 isoforms; epitope coverage needs validation (UniProt); Regulation: Staining regulation is unreported (UniProt). Evidence: UniProt P53539, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to…, Datasheet RP1086, PMC3503985, PMC5678090. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/FOSB/immunohistochemistry-ihc-guide.